Of course, we are proud to be able to introduce this success at the next CPhI in Frankfurt. Hyaluronidase Hyaluronidase: Is a hydrolytisches enzyme, which in its basic elements breaks down hyaluronic acid (D-glucuronic acid and N-acetyl-D-glucosamine) and the ability gives the substances to penetrate deeper into the tissue. It is therefore for example Hyaluronidase in high concentration in the mouth apparatus of leeches in the venom of scorpions, snakes, bees and various pathogenic micro-organisms such as pneumococci and streptococci. Simplified one could say, their function is, the substances, which transported them to disguise the protective mechanisms of organisms. This property is the reason for the numerous important applications in the pharmaceutical industry, but also for the existing natural limitations, which are dictated by the usual extraction from potentially hazardous to the human organism substances (for example, with resulting risk known for a bovine spongiform encephalopathy, also called BSE’). The great progress achieved by the research of Fidia, is a recombinant Hyaluronidase with high safety profile of? to produce pathogenic micro-organisms. This Hyaluronidase by Fidia offers the same efficiency as that of a Hyaluronidase obtained by extraction; However, it is of higher purity, and without the risks associated with transmission of viruses. Hyaluronidase promises in addition as a carrier substance, that the uniform distribution and recording of with her connected agents favors, promoting advanced applications in diseases of high socio-economic importance (Oncology, diabetes, immune deficiency) as well as an optimization of the efficiency of gene therapies and the bioavailability of subcutaneously introduced biological medicinal products; This reduces the need for endo venous therapy.
Some areas where Hyaluronidase can be used efficiently, are: in pharmaceutical preparations for the treatment of Perniones, hemorrhoids, edema, localized inflammation and myocardial infarction; In addition to the local anesthetic in eye surgery; as part of the release system for transdermal drugs to encourage the recording of the organism; in cosmetic surgery to the containment of complications after wrinkle treatments, also with hyaluronic acid; in oncology to suppress the progression of tumour cells; in veterinary medicine as an addition of antibiotic solutions, for example for treating udder infections. About FIDIA Farmaceutici S.p.a.. Fidia Farmaceutici S.p.a.., an internationally recognized Italian company, develops, manufactures and markets innovative medicines, medical devices, and dietary supplements with a high added value, security and efficiency. The activities focus among others on diseases of the musculo-skeletal and tissue repair; in these areas the company is a worldwide leader in the development of products based on hyaluronic acid and its derivatives. Over fifty years of research on the molecular and the related patents, Fidia made today on one of the first places in related research and development, product portfolio and worldwide sales. The company is also leading in research & Development and marketing of technologically processed biological products.